Patent 10472371 was granted and assigned to FORMA Therapeutics on November, 2019 by the United States Patent and Trademark Office.
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).